Sangeetha Balasubramanian in Campbell, California

Additional Medical Specialties Include:
INTERNAL MEDICINE

Medical School: Sorry, her university is not listed
Graduation Year: 2000
The Primary Medical Specialty for Sangeetha Balasubramanian is listed as: Rheumatology
Approximate Years of Experience: 24
PAC (PECOS ID)#: 8628233483
NPI #: 1265640874
NPI Created On: 05/18/2007
NPI Last Updated Listed as: 09/28/2023
Primary Taxonomy Code: 207R00000X
License Number:
A114316
Listed Gender: Female

Forms of insurance accepted by include, but are not limited to:

• Humana
• Medicare

They are listed as accepting new patients.

Languages spoken by staff include: English, Tamil, Kannada, Hindi.

Services and Procedures include:

1. Aspiration and/or injection of large joint or joint capsule
2. Aspiration and/or injection of major joint or joint capsule with recording and reporting using ultrasound guidance
3. Vaccine for influenza for injection into muscle
4. Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour
5. Injection beneath the skin or into muscle for therapy, diagnosis, or prevention
6. Infusion of chemotherapy into a vein up to 1 hour
7. Infusion of chemotherapy into a vein
8. New patient office or other outpatient visit, typically 45 minutes
9. New patient office or other outpatient visit, typically 60 minutes
10. Established patient office or other outpatient visit, typically 15 minutes
11. Established patient office or other outpatient, visit typically 25 minutes
12. Established patient office or other outpatient, visit typically 40 minutes
13. Physician telephone patient service, 11-20 minutes of medical discussion
14. Physician telephone patient service, 21-30 minutes of medical discussion
15. Administration of influenza virus vaccine
16. Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)
17. Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)
18. Injection, denosumab, 1 mg
19. Injection, golimumab, 1 mg, for intravenous use
20. Injection, infliximab, excludes biosimilar, 10 mg